Dyne Therapeutics (NASDAQ:DYN) Given New $38.00 Price Target at HC Wainwright

Dyne Therapeutics (NASDAQ:DYN - Free Report) had its target price decreased by HC Wainwright from $46.00 to $38.00 in a research note issued to investors on Friday,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

DYN has been the topic of several other research reports. Piper Sandler lowered their price objective on shares of Dyne Therapeutics from $53.00 to $48.00 and set an "overweight" rating on the stock in a research note on Friday, February 28th. BMO Capital Markets started coverage on shares of Dyne Therapeutics in a research note on Wednesday, March 12th. They issued an "outperform" rating and a $50.00 price objective on the stock. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $45.00 price objective on shares of Dyne Therapeutics in a research note on Tuesday, January 14th. JPMorgan Chase & Co. lowered their price objective on shares of Dyne Therapeutics from $18.00 to $17.00 and set a "neutral" rating on the stock in a research note on Friday, March 21st. Finally, Guggenheim reaffirmed a "buy" rating on shares of Dyne Therapeutics in a research note on Friday, January 24th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, twelve have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $46.85.

Dyne Therapeutics Stock Up 10.1%

Dyne Therapeutics stock traded up $1.15 during trading hours on Friday, hitting $12.56. 4,777,508 shares of the company traded hands, compared to its average volume of 1,659,780. The firm has a market cap of $1.43 billion, a P/E ratio of -3.53 and a beta of 1.19. The firm's 50-day simple moving average is $10.38 and its two-hundred day simple moving average is $17.85. Dyne Therapeutics has a 1-year low of $6.36 and a 1-year high of $47.45.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.17). On average, equities research analysts predict that Dyne Therapeutics will post -3.44 earnings per share for the current year.

Insider Activity at Dyne Therapeutics

In related news, insider Oxana Beskrovnaya sold 2,598 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $13.95, for a total transaction of $36,242.10. Following the transaction, the insider now directly owns 199,087 shares of the company's stock, valued at approximately $2,777,263.65. The trade was a 1.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Over the last three months, insiders have sold 6,237 shares of company stock valued at $77,760. Corporate insiders own 14.14% of the company's stock.

Institutional Trading of Dyne Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its stake in Dyne Therapeutics by 10.5% in the first quarter. Vanguard Group Inc. now owns 7,406,344 shares of the company's stock valued at $77,470,000 after acquiring an additional 702,418 shares during the last quarter. Janus Henderson Group PLC lifted its stake in Dyne Therapeutics by 8.3% in the fourth quarter. Janus Henderson Group PLC now owns 7,379,309 shares of the company's stock valued at $173,808,000 after acquiring an additional 566,146 shares during the last quarter. Geode Capital Management LLC lifted its stake in Dyne Therapeutics by 1.5% in the fourth quarter. Geode Capital Management LLC now owns 1,887,329 shares of the company's stock valued at $44,476,000 after acquiring an additional 27,916 shares during the last quarter. Jefferies Financial Group Inc. acquired a new stake in Dyne Therapeutics in the fourth quarter valued at approximately $42,408,000. Finally, Orbimed Advisors LLC lifted its stake in Dyne Therapeutics by 73.2% in the fourth quarter. Orbimed Advisors LLC now owns 1,227,080 shares of the company's stock valued at $28,910,000 after acquiring an additional 518,680 shares during the last quarter. 96.68% of the stock is currently owned by institutional investors and hedge funds.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.